'Several approaches' for Vernalis as it backs out of Tris deal

15 June 2018

There has been interest from several parties in buying the UK-based Vernalis (LSE: VER), the company announced as it started to wind down its agreement with Tris Pharma in connection with the ongoing closure of its US commercial operations.

Vernalis decided that a sale would be a prudent way forward earlier this year after accepting that US sales of the cough and cold drug Tuzistra XR (codeine/chlorpheniramine) had been slower than expected.

The company has now announced the end of its deal with USA-based Tris, which had focused on the development and commercialization of multiple novel products focussed on the US prescription cough cold market, as well as programs in its pipeline.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK